Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (DE:2KZ0)
FRANKFURT:2KZ0
RESEARCH TOOLSreports
Holding DE:2KZ0?
Track your performance easily
2KZ0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.18 - €9.35
Previous Close€6.95
Volume0.00
Average Volume (3M)15.00
Market Cap
€52.14M
Enterprise Value-€86.13M
Total Cash (Recent Filing)$164.18M
Total Debt (Recent Filing)$17.61M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 13, 2025EPS Estimate
-€2.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,296,222
10 Day Avg. Volume0
30 Day Avg. Volume15
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.00
Price to Sales (P/S)7.82
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-12.30
Enterprise Value/Gross Profit-12.30
Enterprise Value/Ebitda0.90
Forecast
1Y Price Target
€10.52Price Target Upside51.42% Upside
Rating ConsensusHold
Number of Analyst Covering4
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe IDMC overseeing the PORTOLA trial recommended continuing the AIH study without modification.
Clinical Trial SafetyNo Grade 4 or Grade 5 severe adverse events have been observed in the PORTOLA trial.
Drug EfficacyManagement mentioned some patients managed to taper down steroids to less than 5mg/kg, which might bode well for the efficacy of zeto.
Bears Say
Buyout Offer UncertaintyThe buyout offer appears opportunistic, with an uncertain outcome.
Regulatory ChallengesSkepticism around zeto's program is expected to continue until alignment with the FDA on regulatory path and removal of the partial hold.
Safety ConcernsInvestors are expected to remain cautious on zeto due to safety events, anticipating shares to trade sideways ahead of updates.
---
2KZ0 FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was €4.18 and its highest was €9.35 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Mar 13, 2025 which is in 107 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Nov 12, 2024. The company reported -€2.668 earnings per share for the quarter, beating the consensus estimate of -€3.022 by €0.353.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -€2.63.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 7,296,222 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -€2.668 in its last earnings report, beating expectations of -€3.022. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at N/A.
---
Kezar Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€10.52 (51.42% Upside)
€10.52 (51.42% Upside)
Blogger Sentiment
Bullish
DE:2KZ0 Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.34%
12-Months-Change
Fundamentals
Return on Equity
-54.72%
Trailing 12-Months
Asset Growth
-34.19%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
2KZ0 Stock 12 Month Forecast
Average Price Target
€10.52
▲(51.42% Upside)
Technical Analysis
Kezar Life Sciences
―
Bioxcel Therapeutics
―
Corbus Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering 2KZ0
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
-14.46%
reiterated a buy rating 15 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -14.46% per trade.
---